louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06868927: Targeted Decision Making In Renal Cell Carcinoma Relying on a Radiogenomics Translational Platform
Official title: Targeted Decision Making In Renal Cell Carcinoma Relying on a Radiogenomics Translational Platform
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Renal Tumors
Lead sponsor: IRCCS San Raffaele
Sponsor class: OTHER
First posted: 2025-03-11
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: subjects with a renal tumor up to 4 cm and candidates for surgery

Brief summary: This project aims to provide an accurate strategy to guide the decision making relying on tumor biopsies using standard histology, immunohistochemistry (IHC), spatial transcriptomics, genomics combined with Magnetic Resonance Imaging (MRI) and radiomics. Moreover, the investigators will explore potential markers indicative of response to systemic agents or ablative therapy.


Eligibility criteria: Inclusion Criteria:

* Presence of a renal mass up to 4 cm
* Adult \> 18 years
* Candidate to renal surgery
* Informed consent signed

Exclusion Criteria:

* Contraindication for MRI

Primary outcomes:
measure: accuracy of multiparametric preoperative MRI
timeFrame: At final pathological assessment , at least 1 month after surgery
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT04016727: Variation in Rate of Orthodontic Tooth Movement in Response to Platelet Rich Plasma Therapy
Official title: Variation in Rate of Orthodontic Tooth Movement in Response to Platelet Rich Plasma Therapy
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: Tooth Movement
Keywords: tooth movement
platelet rich plasma
Lead sponsor: Armed Forces Institute of Dentistry, Pakistan
Sponsor class: OTHER
First posted: 2019-07-11
Enrollment: 10
Sex: ALL
Minimum age (years): 11
Maximum age (years): 20
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: PRP from 5 ml blood was prepared and 60 units were injected into the buccal vestibule of patient before initiating canine retraction using NiTi coil spring. Pre and post cervical, incisal and mid distances were measured using Vernier calliper.

Detailed description: Platelet rich plasma was prepared using patients own blood. The production of PRP began with a 6-mL homologous blood sample that was withdrawn from the donor via venupuncture. One milliliter of the blood sample was set apart to determine the concentration of platelets and leukocytes in whole blood. The remaining 5 mL was mixed with an anticoagulant (3.8%, 1-mL sodium citrate) to prevent clotting. The blood sample was centrifuged at 113 g for 5 minutes to separate the plasma containing the platelets from the red cells. The plasma was drawn off the top and centrifuged for an additional 2 minutes at 3772 g to separate the platelets. Suitable platelet concentrations were achieved by the resuspension of PRP with plasma (high platelet concentration, 5 times the concentration in whole blood).

Eligibility criteria: Inclusion Criteria:

* patients requiring first premolar extractions

Exclusion Criteria:

* patients taking any drugs, steroids, NSAIDs and antibiotics
* patients with any co morbid conditions

Primary outcomes:
measure: canine movement in mili meters
timeFrame: 1 month
Secondary outcomes:
Other outcomes:
Locations:
city: Rawalpindi
country: Pakistan
facility: AFID
state: Punjab
Study officials:
affiliation: AFID rawalpindi
name: sana tariq, BDS
role: STUDY_CHAIR
References:
Clinical trial NCT02745327: Nutrition, Overgrowth, and Vaccine Efficacy in Low-income Settings
Official title: A Longitudinal Study of Childhood Intestinal Bacterial Overgrowth, Vaccine Underperformance, and Malnutrition
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Small Intestine Bacterial Overgrowth
Keywords: oral vaccination
nutrition
Lead sponsor: University of Virginia
Sponsor class: OTHER
Collaborators: name: Virginia Commonwealth University
name: International Centre for Diarrhoeal Disease Research, Bangladesh
First posted: 2016-04-20
Enrollment: 270
Sex: ALL
Minimum age (years): 1
Maximum age (years): 7
Standard ages: CHILD
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Bangladeshi infants from the low-income neighborhood of Mirpur, Dhaka

Brief summary: The purpose of this study is to assess the impact of small intestine bacterial overgrowth (SIBO) on childhood nutritional status, growth, and oral vaccine efficacy.


Eligibility criteria: Inclusion Criteria:

* Child previously enrolled in the FIELD STUDIES protocol (enrollments in both studies may occur simultaneously)
* Mother willing to sign informed consent form.
* Healthy infant aged less than 7 days old

Exclusion Criteria:

* Parents are not willing to have child's blood drawn, oral fluid collected, urine collected, or breath testing performed.
* History of seizures, other apparent neurologic disorders, or other congenital abnormalities involving major organ systems.

Primary outcomes:
measure: Glucose-Hydrogen Breath Test
timeFrame: Birth to 2 years
Secondary outcomes:
measure: Fecal Regenerating Islet-Derived 1 Beta (Reg 1B)
timeFrame: Birth to 2 years
measure: Fecal Myeloperoxidase
timeFrame: Birth to 2 years
measure: Serum 25-OH vitamin D
timeFrame: Birth to 2 years
measure: Serum Zinc
timeFrame: Birth to 2 years
measure: Serum Retinol Binding Protein
timeFrame: Birth to 2 years
measure: Serum Cobalamin
timeFrame: Birth to 2 years
measure: Serum Albumin
timeFrame: Birth to 2 years
measure: Lactulose mannitol ratio
timeFrame: 12 weeks of age
measure: Serum Tetanus antibody titers
timeFrame: Birth to 2 years
measure: Serum Polio antibody titers to sabin strains
timeFrame: Birth to 2 years
measure: Oral fluid Tetanus antibody titers
timeFrame: Birth to 2 years
measure: Height
timeFrame: Birth to 2 years
measure: Weight
timeFrame: Birth to 2 years
measure: Head circumference
timeFrame: Birth to 2 years
Other outcomes:
Locations:
city: Dhaka
country: Bangladesh
facility: The International Centre for Diarrhoeal Disease Research, Bangladesh
Study officials:
affiliation: University of Virginia
name: William A Petri, M.D., PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Donowitz JR, Pu Z, Lin Y, Alam M, Ferdous T, Shama T, Taniuchi M, Islam MO, Kabir M, Nayak U, Faruque ASG, Haque R, Ma JZ, Petri WA Jr. Small Intestine Bacterial Overgrowth in Bangladeshi Infants Is Associated With Growth Stunting in a Longitudinal Cohort. Am J Gastroenterol. 2022 Jan 1;117(1):167-175. doi: 10.14309/ajg.0000000000001535.
Clinical trial NCT03660527: Nutritional Status of Chinese Residents
Official title: Nutritional Status of Residents From the Chinese National Health and Nutrition Survey During 2010-2012
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Nutrition Status of Chinese Residents
Keywords: hemoglobin, vitamin D, vitamin A, TC, TG, HDLC
Lead sponsor: Centers for Disease Control and Prevention, China
Sponsor class: OTHER_GOV
First posted: 2018-09-06
Enrollment: 41420
Sex: ALL
Minimum age (years): 6
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: OTHER
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: Participanted in China national nutrition and health survey (CNNHS) 2010-2012; Aged above 6 years old; Had blood taken;

Exclusion Criteria:

Brief summary: In this study, we analyzed the nutritional status of Chinese residents aged above 6y. The indicators such as the hemoglobin, vitamin D, vitamin A and TG, TC and HDLC were also included. Related risk factors (such as age, region type, ethnicity, bodyweight, height, education, season, smoke habit, etc).


Eligibility criteria: Inclusion Criteria:

* Participanted in China national nutrition and health survey (CNNHS) 2010-2012; Aged above 6 years old; Had blood taken;

Exclusion Criteria:

* No.

Primary outcomes:
measure: anemia status
timeFrame: through study completion, an average of 1 year
measure: vitamin D deficiency
timeFrame: through study completion, an average of 1 year
measure: vitamin A deficiency
timeFrame: through study completion, an average of 1 year
measure: Metabolic syndrome
timeFrame: through study completion, an average of 1 year
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
citation: GBD 2015 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016 Oct 8;388(10053):1545-1602. doi: 10.1016/S0140-6736(16)31678-6.
Clinical trial NCT01285427: Clinical Protocol SeCore, uTYPE and 3500 Dx System
Official title: SeCore Sequencing Kit and 3500xl Dx Genetic Analyzer Clinical Performance Testing vs. SSP UniTray
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Human Leukocyte Antigens (HLA)
Keywords: DNA, sequencing
Identification and definition of Class I and II Human Leukocyte Antigens (HLA)
Lead sponsor: Life Technologies Corporation
Sponsor class: INDUSTRY
First posted: 2011-01-28
Enrollment: 300
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Sampling method: NON_PROBABILITY_SAMPLE
Study population: A, B, C, DRB1, DRB3/4/5, DQB1, DPB1 loci

Brief summary: The purpose of this study is to compare the Invitrogen SeCore(R) sequencing system and uTYPE(R) interpretation software to the predicate device Invitrogen SSP UniTray(R) with UniMatch(R) interpretation software and show 95% concordance with 90% confidence.

Detailed description: Testing will be performed on A, B, C, DRB1, DRB3/4/5, DQB1, and DPB1 loci. Additionally, testing will be performed using the following locus specific Group Specific Sequencing Primers: A, B, Cw, DPB1, DQB1 and DRB.

Eligibility criteria: Inclusion Criteria:

* Deidentified leftover blood samples

Primary outcomes:
measure: All SeCore® Kits,Primary Analysis of Concordance Rate (Clopper-Pearson CI)
timeFrame: 10 weeks
measure: SeCore® Kit, A Locus, Primary Analysis of Concordance Rate (Clopper-Pearson CI)
timeFrame: 10 weeks
measure: SeCore® Kit, B Locus (Single Amp), Primary Analysis of Concordance Rate (Clopper-Pearson CI)
timeFrame: 10 weeks
measure: SeCore® Kit, C Locus, Primary Analysis of Concordance Rate (Clopper-Pearson CI)
timeFrame: 10 weeks
measure: SeCore® Kit, DPB1 Locus, Primary Analysis of Concordance Rate (Clopper-Pearson CI)
timeFrame: 10 weeks
measure: SeCore® Kit, DQB1 Locus, Primary Analysis of Concordance Rate (Clopper-Pearson CI)
timeFrame: 10 weeks
measure: SeCore® Kit, DRB1 Locus, Primary Analysis of Concordance Rate (Clopper-Pearson CI)
timeFrame: 10 weeks
measure: SeCore® Kit, DR Group Kit (DRB1 Locus), Primary Analysis of Concordance Rate (CI)
timeFrame: 10 weeks
measure: SeCore® Kit, DR Group Kit (DRB345 Loci), Primary Analysis of Concordance Rate Clopper-Pearson CI)
timeFrame: 10 weeks
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Life Technologies
name: Deanna Vella
role: STUDY_CHAIR
References:
Clinical trial NCT04301427: Smallest Significant Value in Osteodensitomery in an Obese Population
Official title: Smallest Significant Value in Osteodensitomery in an Obese Population
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Obesity
Keywords: Bone density
Osteoporosis
Osteopenia
Obesity
OSteodensitometry
Lead sponsor: CHU de Reims
Sponsor class: OTHER
First posted: 2020-03-10
Enrollment: 120
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: The aim of this study is to determined the smallest significant value in osteodensitometry in obese population. The study population will be divided in 3 groups according to their BMI.

Bone mineral density will be measured twice in osteodensitometry, then the smallest significant value will be determined.

Our hypothesis is that the smallest significant value that we use in an non-obese population can be different in an obese population.

Detailed description: The aim of this study is to determined the smallest significant value in osteodensitometry in obese population.

There will be at least 120 patient included. The study population will be divided in 3 groups according to their BMI : the first group has a BMI between 30 and 35 kg/cm² ; the second group has a BMI between 35 et 40 kg/cm² ; and the third group has a BMI over 40 kg/cm².

Patients will be referred by their doctors (rheumatologist and others) to evaluate their bone mineral density in osteodensitometry at CHU of Reims. Patients will be informed of the aim of the study by the prescriptor of the osteodensitometry.

The osteodensitometry will be executed by a nurse. Patients will have to complete a questionnaire about their medical history and their medications.

Bone mineral density will be measured twice in osteodensitometry, at the lumbar spine, the hip and the femur. This exam lasts approximately 40 minutes.

Then the smallest significant value will be determined by comparing each measure for every patients.

Eligibility criteria: Inclusion criteria :

* Major patients
* Patients referred to the CHU of Reims to make an osteodensitometric evaluation of their bone mineral density
* BMI \> 30 kg/cm²
* Patient affiliated to a health insurance plan
* Patients who have signed informed consent

Exclusion criteria :

* Minor patients
* Pregnant women
* Patients protected by the law

Primary outcomes:
measure: osteodensitometry in obese population
timeFrame: Day 1
Secondary outcomes:
measure: osteodensitometry in obese population with BMI between 30 and 35 kg/cm²
timeFrame: Day 1
measure: osteodensitometry in obese population with BMI between 35 and 40 kg/cm²
timeFrame: Day 1
measure: osteodensitometry in obese population with BMI over 40 kg/cm²
timeFrame: Day 1
Other outcomes:
Locations:
city: Reims
country: France
facility: Damien JOLLY
Study officials:
References:
Clinical trial NCT04011527: The Prospective Segeberg Registry for Rotational Atherectomy in Coronary Lesion/s
Official title: A Prospective Follow-up Assessment in Bad Segeberg With Patients Undergoing a Rotational Atherectomy in Coronary Lesion/s
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Coronary Artery Disease
Keywords: Calcified coronary artery lesions
Lead sponsor: Segeberger Kliniken GmbH
Sponsor class: OTHER
First posted: 2019-07-08
Enrollment: 1500
Sex: ALL
Minimum age (years): 18
Maximum age (years): 100
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with coronary artery disease undergoing a rotational atherectomy in coronary lesion/s

Brief summary: A Prospective Follow-up Assessment in Bad Segeberg with Patients undergoing a Rotational Atherectomy in Coronary Lesion/s

Detailed description: A prospective single center registry including all patients treated with Rotational Atherectomy in Coronary Lesion/s at the Heart Center, Bad Segeberg, Germany. Patients undergo a routine clinical follow-up schedule, including a long-term follow-up.

Eligibility criteria: Inclusion Criteria:

* All patients undergoing a rotational atherectomy of coronary lesion/s

Exclusion Criteria:

* None

Primary outcomes:
measure: Rate of in-hospital and long-term cardiovascular adverse events in percent
timeFrame: 2 years
Secondary outcomes:
Other outcomes:
Locations:
city: Bad Segeberg
country: Germany
facility: Herzzentrum Segeberger Kliniken GmbH
Study officials:
affiliation: Herzzentrum Segeberger Kliniken GmbH
name: Gert Richardt, Prof., MD
role: STUDY_DIRECTOR
References:
Clinical trial NCT00875927: Effects of Breezy Candy on Halitosis
Official title: Breezy Candy Halitosis Study
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE1
PHASE2
Conditions: Halitosis
Keywords: Halitosis
Lead sponsor: Breezy Industries Ltd.
Sponsor class: INDUSTRY
First posted: 2009-04-06
Enrollment: 75
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Users of Breezy candy will utilize the candy's abrasiveness to scrape tongue surface. The scraping action together with the release of compounds contained inside the abrasive microcapsules will result in significant reduction of oral halitosis.


Eligibility criteria: Inclusion Criteria:

* adult
* healthy
* male
* female
* bad breath

Exclusion Criteria:

* subject suffering from Diabetes
* subject suffering from renal disease
* pregnant women
* cigarette smokers
* any illness of oral cavity for the last 3 months
* subjects undergoing chemotherapy
* treatment by antibiotic
* treatment by anti-inflammatory

Primary outcomes:
measure: Users of Breezy Candy will have fresher breath over Control
timeFrame: 150 minutes
Secondary outcomes:
Other outcomes:
Locations:
city: Hadera
country: Israel
facility: Hillel Yaffe Medical Center
Study officials:
affiliation: Mouth and Jaw institute, Hillel Yaffe Medical Center
name: Shlomo Barak, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03817827: Effect of Acupuncture and Diet Modification on amenorrheaIN FEMALE ATHLETE TRIAD
Official title: Effect of Acupuncture and Diet Modification on Amenorrhea in Female Athlete Triad
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Female Athlete Triad
Keywords: sports injury
female athlete triad
acupuncture
Lead sponsor: National Research Centre, Egypt
Sponsor class: OTHER
First posted: 2019-01-28
Enrollment: 0
Sex: FEMALE
Minimum age (years): 17
Maximum age (years): 25
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The present study will be designed to investigate the effect of acupuncture and diet modification using soy products on amenorrhea in female athlete triad.

For this purpose this study will be carried out on sixty female athletes participating gymnastics. They will be recruited from Sports Medicine specialized center in Nasr City, their ages will range from 17 to 25 years old and their BMI will be \< 20 Kg/m2 .

Detailed description: The subjects will be divided into three groups equal in number, matched for measured variable:

Group (A): Acupuncture only will be used in this group for 30 minutes, three times per week for twelve weeks. The acupuncture needles were inserted in points located on the abdomen.

Group (B): This group will receive only the diet modification contains soy products (phytoestrogen) as 100 milliliter soy milk and 100 grams soy beans daily in the morning as a breakfast alone to ensure its absorption, this dose had been taken for 12 weeks.

Group (C): This group will receive both acupuncture therapy for 30 minutes, three times per week for 12 weeks and diet modification contains soy products as 100 milliliter soy milk and 100 grams soy beans daily in the morning for 12 weeks.

Eligibility criteria: Inclusion Criteria:

* All patients suffering from athletic amenorrhea.
* Their age will be ranged from 17-25 years old.
* Their body mass index will be less than 18.5 kg/m2.
* No history of previous pregnancies.
* No history of any pathological disease causing amenorrhea.
* They are medically stable and consented to participate in the study.

Exclusion Criteria:

* Patients with gynecological diseases that may cause amenorrhea.
* Patients using contraceptive pills.
* Patients using hormonal treatment.
* Patients using induction of ovulation methods.
* Patients following any other diet modification method.
* Patients who receive any drug with side effect of amenorrhea.

Primary outcomes:
measure: follicle stimulating hormone
timeFrame: three months
measure: Luteinizing hormone
timeFrame: three months
measure: estradiol 2
timeFrame: three months
Secondary outcomes:
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Sports medicine speciaized center
state: Nasr City
Study officials:
References:
Clinical trial NCT01282827: Paraorbital-Occipital Electric Stimulation in Patients With Optic Neuropathy (BCT_optnerve)
Official title: Paraorbital-occipital Alternating Electric Current Stimulation in Patients With Optic Neuropathy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Visual Impairment
Lead sponsor: University of Magdeburg
Sponsor class: OTHER
Collaborators: name: EBS Technologies GmbH
First posted: 2011-01-25
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Non-invasive brain stimulation can increase cortical excitability in the visual system, but it is not known if this is of clinical value. The investigators now assessed if repetitive, transcranial alternating current stimulation (rtACS) can improve visual field size in patients with optic nerve damage. The investigators hypothesized that rtACS would improve visual functions with the defective visual field sectors of the visual field (primary outcome measure).

Detailed description: exploratory, randomized, controlled study

Eligibility criteria: Inclusion Criteria:

* residual vision
* patients with optic nerv lesion
* lesion age at least 6 months
* stable visual field defect

Exclusion Criteria:

* electric or electronic implants such as pace maker
* any metal artefacts in head and truncus
* epilepsia
* photosensitive epilepsy as determines by EEG
* autoimmune illnesses in acute stage
* mental diseases such e.g. schizophrenia etc.
* diabetes causing diabetic retinopathy
* addiction
* high blood pressure
* unstable or high level intraocular pressure (i.e. \> 27 mmHg)
* retinitis pigmentosa
* pathological nystagmus
* presence of an un-operated tumor or tumor recidive

Primary outcomes:
measure: Detection accuracy (DA) change in percent over baseline within defective visual field sectors
timeFrame: between baseline and 60 days after stimulation
Secondary outcomes:
measure: Visual Parameters 1
timeFrame: baseline to 60 days after stimulation
measure: Visual Parameters 2
timeFrame: baseline to 60 days after stimulation
measure: Visual Parameters 3
timeFrame: baseline to 60 days after stimulation
measure: Visual Parameters 4
timeFrame: baseline to 60 days after stimulation
measure: EEG parameters
timeFrame: baseline to 60 days after stimulation
Other outcomes:
Locations:
city: Berlin
country: Germany
facility: Klinik für Neurologie, Charité Campus Mitte, Universitätsmedizin Berlin
city: Magdeburg
country: Germany
facility: Institut für Medizinische Psychologie, Leipziger Str. 44
Study officials:
affiliation: University of Magdeburg
name: Bernhard A Sabel, Prof. Dr.
role: PRINCIPAL_INVESTIGATOR
References: